Ovarian Cancer

By going public with the details of their cancer journeys, patients and survivors can pave the way for understanding and support.

While half of women with gynecologic cancer reported experiencing significant fatigue during treatment, only 8% of survivors had symptoms regress without intervention.

The FDA has granted a priority review designation to a supplemental biologics license application for Zejula for the treatment of certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer.

Sue Friedman, founder and executive director of FORCE, discussed how a breast cancer diagnosis at age 33 and a family history of cancer led to the creation of Facing Our Risk of Cancer Empowered.

Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects. Luckily, doctors have a variety of ways to relieve or prevent these discomforts. At the same time, scientists are working to develop new treatments that may be both efficacious and easier for patients to tolerate.

A essay nominating Kimberly Spina, B.S.N., RN for CURE®’s Extraordinary Healer® Award, written by Stephanie Fraser, M.S.W., of The University of Vermont Cancer Center.

"We hope that this array of articles, while offering comprehensive information about cutting-edge treatments, will also serve as a reminder of the shared experience of those in the cancer community and the sense of connection it can bring," said Chairman and CEO, Mike Hennessy, Sr. 

The seven-time Olympic medalist found strength in her competitive spirit through cancer.

I’m running this marathon to win it. I want to say don’t let a wall stop you; keep running, keep fighting!

A second ovarian cancer recurrence in three years prompted this review of lessons learned. If I could go back three and a half years and give advice to my newly diagnosed self, what would I say?